Abstract
Oligometastasis represents an intermediate disease stage between localized and widely metastatic cancer. Efficient identification of patients with oligometastasis remains a barrier for accrual on clinical trials of oligometastasis-directed therapy. Here we review the prospect of circulating tumor DNA-based monitoring to promote sensitive, specific, and cost-efficient detection of cancer recurrence during posttreatment surveillance. Thus, an impetus for the development and implementation of clinical-grade circulating tumor DNA assays should be for the positive impact they will have on clinical investigations of oligometastasis-directed therapy.
Original language | English (US) |
---|---|
Pages (from-to) | 116-123 |
Number of pages | 8 |
Journal | Cancer Journal (United States) |
Volume | 26 |
Issue number | 2 |
DOIs | |
State | Published - Mar 1 2020 |
Keywords
- Biomarkers
- circulating tumor DNA
- oligometastasis
- radiotherapy
ASJC Scopus subject areas
- Oncology
- Cancer Research